New combo therapy aims to slow advanced prostate cancer

NCT ID NCT04704505

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special hormone therapy (bipolar androgen therapy) to a targeted radiation drug (radium-223) can slow the growth of prostate cancer that has spread to bones and stopped responding to standard hormone treatments. About 47 men with this advanced cancer will receive both treatments every 28 days for up to 6 cycles. The goal is to see how long the cancer stays under control and to monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amber Michalik

    RECRUITING

    Baltimore, Maryland, 20707, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moinhos de Vento Hospital

    NOT_YET_RECRUITING

    Porto Alegre, 90560-010, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••